贝伐单抗治疗转移性结肠癌的肠穿孔:发病率，病因学和管理

Current surgery Pub Date : 2006-09-01 DOI:10.1016/j.cursur.2006.06.002

John H. Heinzerling BA , Sergio Huerta MD

{"title":"贝伐单抗治疗转移性结肠癌的肠穿孔:发病率，病因学和管理","authors":"John H. Heinzerling BA , Sergio Huerta MD","doi":"10.1016/j.cursur.2006.06.002","DOIUrl":null,"url":null,"abstract":"<div><p>Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.</p></div>","PeriodicalId":75762,"journal":{"name":"Current surgery","volume":"63 5","pages":"Pages 334-337"},"PeriodicalIF":0.0000,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cursur.2006.06.002","citationCount":"95","resultStr":"{\"title\":\"Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management\",\"authors\":\"John H. Heinzerling BA , Sergio Huerta MD\",\"doi\":\"10.1016/j.cursur.2006.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.</p></div>\",\"PeriodicalId\":75762,\"journal\":{\"name\":\"Current surgery\",\"volume\":\"63 5\",\"pages\":\"Pages 334-337\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.cursur.2006.06.002\",\"citationCount\":\"95\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0149794406000894\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current surgery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149794406000894","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 95

摘要

Avastin (Bevacizumab)是最近开发的针对血管内皮生长因子(VEGF)受体的单克隆抗体，可提高转移性结直肠癌患者的生存率。肠穿孔是与阿瓦斯汀使用相关的未知病因的已知危险因素。在本报告中，发病率，危险因素，典型的表现，和管理的病人，这种并发症的描述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management

Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current surgery

自引率

0.00%

发文量